States insist on obesity coverage
More states are telling HMOs and other health insurers to pick up the tab for pharmaceuticals and other forms of obesity treatment.
As the evidence grows regarding the role that obesity plays in many illnesses, more states are telling HMOs and other health insurers to pick up the tab for pharmaceuticals and other forms of obesity treatment.
According to StateLine,⢠Newtown, PA-based Scott-Levin's tracking system for government legislation and regulation, recent laws have taken effect in:
•Â Georgia, where the governor signed the Morbid Obesity Anti-Discrimination Act, which requires insurers to provide major medical benefits for treatment of morbid obesity.
•Â Indiana, where the governor signed a bill to require health insurers and HMOs to provide coverage for morbid obesity.
•Â Virginia, where the governor signed a bill to require coverage of gastric bypass surgery and "other recognized methods."
According to Scott-Levin, these measures represent just the beginning of this trend. In all, 26 states have recently proposed legislation addressing obesity-related issues.
The legislation is diverse. Some bills would establish commissions to study obesity and its health consequences. Others would regulate existing prescription and over-the-counter therapies for weight loss.
Underlying all this activity is the goal of state health policy-makers to better understand the true cost of obesity. PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
